Human Wnt9a ELISA Kit

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Wnt9a also known as Wingless-related integration site 9A is a secreted glycoprotein with a molecular mass of approximately 39 kDa. This protein forms part of the Wnt family which comprises signaling molecules involved in various developmental processes. Wnt9a is expressed in several tissues including the brain kidneys and skeletal tissues during embryonic development but it can also be found in adult tissues. Its expression pattern indicates a role in spatial and temporal regulation during cell growth and differentiation.

Biological function summary

Wnt9a functions in the regulation of cell proliferation migration and fate determination. It operates as part of larger protein complexes that include other Wnt family members and co-receptors such as Frizzled receptors. Wnt9a plays a significant role in osteoblast differentiation and skeletal development. It also contributes to the patterning of mesenchymal cells into chondrocytes during skeletal morphogenesis. These biological activities highlight its essential function in both developmental stages and tissue maintenance.

Pathways

Wnt9a acts through the canonical Wnt/β-catenin signaling pathway and is also involved in the non-canonical Wnt signaling pathway. Within these pathways it interacts with LRP5/6 receptors and related proteins like Dishevelled (Dvl) and Axin. The canonical pathway promotes gene transcription activation whereas the non-canonical pathway influences cell movements and organization. These interactions highlight Wnt9a’s role in the broader signaling cascades important for embryogenesis and homeostasis.

Associated diseases and disorders

Wnt9a is associated with skeletal malformations such as Robinow syndrome and bone density disorders. Wnt9a mutations can disrupt normal skeletal development leading to abnormal growth and bone formation. In this context interactions with other proteins like BMP4 and Sox9 become disrupted contributing to the pathogenesis of these conditions. Studies continue to explore the therapeutic potential of targeting Wnt9a pathways for treating these skeletal disorders.